全文获取类型
收费全文 | 1316篇 |
免费 | 142篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 39篇 |
妇产科学 | 18篇 |
基础医学 | 164篇 |
口腔科学 | 25篇 |
临床医学 | 115篇 |
内科学 | 269篇 |
皮肤病学 | 30篇 |
神经病学 | 51篇 |
特种医学 | 165篇 |
外科学 | 115篇 |
综合类 | 65篇 |
预防医学 | 190篇 |
眼科学 | 17篇 |
药学 | 85篇 |
中国医学 | 7篇 |
肿瘤学 | 108篇 |
出版年
2023年 | 16篇 |
2022年 | 15篇 |
2021年 | 39篇 |
2020年 | 23篇 |
2019年 | 32篇 |
2018年 | 40篇 |
2017年 | 27篇 |
2016年 | 54篇 |
2015年 | 79篇 |
2014年 | 52篇 |
2013年 | 51篇 |
2012年 | 75篇 |
2011年 | 77篇 |
2010年 | 59篇 |
2009年 | 59篇 |
2008年 | 50篇 |
2007年 | 54篇 |
2006年 | 43篇 |
2005年 | 42篇 |
2004年 | 25篇 |
2003年 | 19篇 |
2002年 | 18篇 |
2001年 | 23篇 |
2000年 | 18篇 |
1999年 | 19篇 |
1998年 | 32篇 |
1997年 | 51篇 |
1996年 | 40篇 |
1995年 | 34篇 |
1994年 | 33篇 |
1993年 | 21篇 |
1992年 | 18篇 |
1991年 | 14篇 |
1990年 | 13篇 |
1989年 | 29篇 |
1988年 | 28篇 |
1987年 | 19篇 |
1986年 | 19篇 |
1985年 | 11篇 |
1984年 | 13篇 |
1983年 | 10篇 |
1982年 | 12篇 |
1981年 | 8篇 |
1980年 | 11篇 |
1978年 | 3篇 |
1977年 | 10篇 |
1976年 | 7篇 |
1974年 | 4篇 |
1972年 | 6篇 |
1965年 | 3篇 |
排序方式: 共有1474条查询结果,搜索用时 15 毫秒
61.
目的 研究中药燕滨扶正胶囊治疗肝硬化(代偿期或失代偿期)临床疗效。方法 选择代偿期及失代偿期肝硬化患者41例,随机分为治疗组(21例)及对照组(20例)。治疗组给予燕滨扶正胶囊1500 mg/次,口服,2次/日。对照组给予扶正化瘀胶囊2500 mg/次,3次/日。两组疗程均为48周。两组依据病情给予抗病毒,护肝降酶、对症支持等一般治疗(替比夫定、甘利欣、消炎利胆片、茵栀黄胶囊等),观察两组患者症状、血常规、肝功能、门静脉宽度、腹水、肝脏及脾脏形态。结果 中药燕滨扶正胶囊联合抗病毒药物可使代偿期及失代偿期肝硬化患者门静脉宽度、脾肿大回缩或复常,可使纤维化指标复常或大幅下降且肝脏功能好转或复常。结论 燕滨扶正胶囊可改善肝硬化。 相似文献
62.
Huang W Begum R Barber T Ibba V Tee NC Hussain M Arastoo M Yang Q Robson LG Lesage S Gheysens T Skaer NJ Knight DP Priestley JV 《Biomaterials》2012,33(1):59-71
Various attempts have been made to develop artificial conduits for nerve repair, but with limited success. We describe here conduits made from Bombyx mori regenerated silk protein, and containing luminal fibres of Spidrex®, a silk-based biomaterial with properties similar to those of spider silk. Assessment in vitro demonstrated that Spidrex® fibres support neurite outgrowth. For evaluation in vivo, silk conduits 10 mm in length and containing 0, 100, 200 or 300 luminal Spidrex® fibres, were implanted to bridge an 8 mm gap in the rat sciatic nerve. At 4 weeks, conduits containing 200 luminal Spidrex® fibres (PN200) supported 62% and 59% as much axon growth as autologous nerve graft controls at mid-conduit and distal nerve respectively. Furthermore, Spidrex® conduits displayed similar Schwann cell support and macrophage response to controls. At 12 weeks, animals implanted with PN200 conduits showed similar numbers of myelinated axons (81%) to controls, similar gastrocnemius muscle innervation, and similar hindpaw stance assessed by Catwalk footprint analysis. Plantar skin innervation was 73% of that of controls. PN200 Spidrex® conduits were also effective at bridging longer (11 and 13 mm) gaps. Our results show that Spidrex® conduits promote excellent axonal regeneration and function recovery, and may have potential for clinical application. 相似文献
63.
64.
65.
目的:探讨前后路联合手术治疗髋臼双柱骨折的效果并分析影响疗效的相关因素。方法:2007年8月至2009年7月收治髋臼双柱骨折患者19例,男13例,女6例;年龄27~52岁,平均39.6岁。高位双柱骨折11例,低位双柱骨折8例,双柱骨折累及骶髂关节1例。受伤至手术时间4~11 d,平均5.8 d。患者均采用前后联合入路手术,重建钢板和螺钉内固定。结果:除1例死亡外本组全部获随访,随访时间12~18个月,平均13.6个月。关节功能根据Harris评分标准,术后功能优9例,良7例,可2例。结论:经前后路联合切开复位内固定治疗髋臼双柱骨折疗效满意。 相似文献
66.
目的:性治疗法目前尚未普及,本研究旨在评价性治疗法联合西地那非治疗勃起功能障碍(ED)的疗效。方法:根据治疗方法的不同将在本院治疗随访过的3130例维吾尔族ED患者分成2组。对照组625例,单纯口服西地那非3个月;试验组2505例,采用性治疗法联合西地那非治疗3个月。采用国际勃起功能问卷表(IIEF-5)在各组治疗前、后进行疗效评估,并随访12个月。结果:对照组治疗前、后及在6个月、12个月随访的IIEF-5评分分别为12.80±3.76、18.10±2.61、17.35±2.73和16.64±2.63;试验组治疗前、后及在6个月、12个月随访的IIEF-5评分分别为12.73±3.52、19.06±4.07、19.86±2.42和20.47±2.38。两组治疗前后IIEF-5评分自身对比差异均有显著性(P<0.05)。组间比较,试验组较对照组6个月和12个月随访IIEF-5评分均有显著性差异(P<0.05)。结论:性治疗法联合西地那非治疗ED的效果优于单纯西地那非治疗,并在12个月的随访中稳定性良好。 相似文献
67.
BD Heckman KA Holroyd G Tietjen FJ O'Donnell L Himawan C Utley R Watakakosol & M Stillman 《Cephalalgia : an international journal of headache》2009,29(6):650-661
This study sought to determine if Whites and African-Americans respond similarly to headache treatment administered in 'real-world' headache specialty treatment clinics. Using a naturalistic, longitudinal design, 284 patients receiving treatment for headache disorders completed 30-day daily diaries that assessed headache frequency and severity at pretreatment and 6-month follow-up and also provided data on their headache disability and quality of life at pretreatment and 1-, 2- and 6-month follow-up. Controlling for socioeconomic status and psychiatric comorbidity, hierarchical linear models found that African-Americans and Whites reported significant reductions in headache frequency and disability and improvements in life quality over the 6-month treatment period. African-Americans, unlike Whites, also reported significant decreases in headache severity. Nevertheless, Africans-Americans had significantly more frequent and disabling headaches and lower quality of life after treatment relative to Whites. Although Whites and African Americans responded favourably to headache treatments, more efficacious treatments are needed given the elevated level of headache frequency that remained in both racial groups following treatment. 相似文献
68.
69.
70.
ER Brown KA Charles SA Hoare RL Rye DI Jodrell RE Aird R Vora U Prabhakar M Nakada RE Corringham M DeWitte C Sturgeon D Propper FR Balkwill JF Smyth 《Annals of oncology》2008,19(7):1340-1346
BACKGROUND: Tumour necrosis factor-alpha (TNF-alpha) is an important regulator of the chronic inflammation contributing to tumour progression. Infliximab, an anti-TNF-alpha monoclonal antibody was investigated in this trial of patients with advanced cancer. The primary objectives were to determine the safety profile and biological response of infliximab in a cancer population. Clinical response was a secondary objective. PATIENTS AND METHODS: Forty-one patients received infliximab at 5 mg/kg (n = 21) or 10 mg/kg (n = 20) i.v. at 0 and 2 weeks and then every 4 weeks. Post-treatment samples were measured for changes in plasma and serum TNF-alpha, CCL2, IL-6 and C-reactive protein (CRP). RESULTS: Infliximab was well tolerated with no dose-limiting toxic effects. At both doses of infliximab, neutralisation of serum TNF-alpha was observed after 1 h while plasma CCL2, IL-6 and serum CRP were decreased 24 and 48 h following infliximab administration. Seven patients experienced disease stablisation (range 10-50+ weeks). There was no evidence of disease acceleration in any patient. CONCLUSIONS: Infliximab treatment was safe and well tolerated in patients with advanced cancer. There was evidence of biological activity with baseline TNF-alpha and CCL2 being correlated with infliximab response. 相似文献